SALTS Act

Bill: 115-s-207
Sponsor: full_name: Sen. Klobuchar, Amy [D-MN]
Introduced: 2017-01-24
Policy area: Crime and Law Enforcement
Subjects: Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Evidence and witnesses

Marketing and advertising
Latest action: action_date: 2018-06-19
text: Placed on Senate Legislative Calendar under General Orders. Calendar No. 472.

Summaries:
action_date: 2017-01-24
action_desc: Introduced in Senate
text: <p> <p><b>Synthetic Abuse and Labeling of Toxic Substances Act of 2017 or the SALTS Act</b></p> <p>This bill amends the Controlled Substances Act to set forth factors that may be considered as evidence to determine whether a controlled substance analogue is intended for human consumption. (Under current law, a controlled substance analogue that is intended for human consumption is treated as a schedule I controlled substance. A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.) </p>

action_date: 2018-06-19
action_desc: Reported to Senate without amendment
text: <p><b>Synthetic Abuse and Labeling of Toxic Substances Act of 2017 or the SALTS Act</b></p> <p>(Sec. 2) This bill amends the Controlled Substances Act to set forth factors that may be considered as evidence to determine whether a controlled substance analogue is intended for human consumption. (Under current law, a controlled substance analogue that is intended for human consumption is treated as a schedule I controlled substance. A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.) </p>

tv_txt: II 115th CONGRESS 1st Session S. 207 IN THE SENATE OF THE UNITED STATES January 24, 2017 Ms. Klobuchar (for herself, Mr. Graham , Mrs. Feinstein , Mr. Grassley , Mr. Whitehouse , Mr. Cornyn , Mr. Blumenthal , Mr. Tillis , and Mr. Warner ) introduced the following bill; which was read twice and referred to the Committee on the Judiciary A BILL To amend the Controlled Substances Act relating to controlled substance analogues.

1. Short title This Act may be cited as the Synthetic Abuse and Labeling of Toxic Substances Act of 2017 or the SALTS Act . 2. Controlled substance analogues Section 203 of the Controlled Substances Act ( 21 U.S.C. 813 ) is amended— (1) by striking A controlled and inserting (a) In general .—A controlled ; and (2) by adding at the end the following: (b) Determination In determining whether a controlled substance analogue was intended for human consumption under subsection (a), evidence related to the following factors may be considered, along with all other relevant evidence: (1) The marketing, advertising, and labeling of the substance. (2) The known efficacy or usefulness of the substance for the marketed, advertised, or labeled purpose. (3) The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold. (4) The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance. (5) Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means. (c) Limitation For purposes of this section, the existence of evidence that a substance was not marketed, advertised, or labeled for human consumption shall not preclude the Government from establishing, based on all the evidence, that the substance was intended for human consumption. .

tv_txt: II Calendar No. 472 115th CONGRESS 2d Session S. 207 IN THE SENATE OF THE UNITED STATES January 24, 2017 Ms. Klobuchar (for herself, Mr. Graham , Mrs. Feinstein , Mr. Grassley , Mr. Whitehouse , Mr. Cornyn , Mr. Blumenthal , Mr. Tillis , Mr. Warner , Mr. Hatch , Ms. Hassan , Mr. Rubio , Mr. Markey , Mr. Kennedy , Ms. Smith , and Mr. Coons ) introduced the following bill; which was read twice and referred to the Committee on the Judiciary June 19, 2018 Reported by Mr. Grassley , without amendment A BILL To amend the Controlled Substances Act relating to controlled substance analogues.

1. Short title This Act may be cited as the Synthetic Abuse and Labeling of Toxic Substances Act of 2017 or the SALTS Act . 2. Controlled substance analogues Section 203 of the Controlled Substances Act ( 21 U.S.C. 813 ) is amended— (1) by striking A controlled and inserting (a) In general .—A controlled ; and (2) by adding at the end the following: (b) Determination In determining whether a controlled substance analogue was intended for human consumption under subsection (a), evidence related to the following factors may be considered, along with all other relevant evidence: (1) The marketing, advertising, and labeling of the substance. (2) The known efficacy or usefulness of the substance for the marketed, advertised, or labeled purpose. (3) The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold. (4) The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance. (5) Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means. (c) Limitation For purposes of this section, the existence of evidence that a substance was not marketed, advertised, or labeled for human consumption shall not preclude the Government from establishing, based on all the evidence, that the substance was intended for human consumption. .

June 19, 2018 Reported without amendment